Cigna Corporation
HealthcareNYSE:CI · New York Stock Exchange
+$3.24 today
Vol 0.53M · Avg 1.65M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$277.9B of revenue converted into $6.3B of net income for the selected period. Gross margin is 9.3% and net margin is 2.3%, showing how much revenue survives after costs and taxes. EPS is $23.58, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $275.0B +11.3% | $247.1B +26.6% | $195.3B +8.2% | $180.5B +3.7% | $174.1B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $249.0B +12.6% | $221.2B +30.0% | $170.1B +8.3% | $157.0B +3.9% | $151.1B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $26.0B +0.1% | $26.0B +3.1% | $25.2B +7.1% | $23.5B +2.4% | $23.0B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 9.5% -1.1pp | 10.5% -2.4pp | 12.9% -0.1pp | 13.0% -0.2pp | 13.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $14.0B -3.9% | $14.6B +1.7% | $14.3B +9.8% | $13.0B +2.0% | $12.8B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $16.9B +1.9% | $16.5B -0.6% | $16.6B +10.6% | $15.1B +0.3% | $15.0B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.6B +50.1% | $1.8B -3.2% | $1.8B -2.4% | $1.9B +3.1% | $1.8B | $374.2M | $1.2B | $631.8M |
| EBITDA | $11.6B +1.4% | $11.4B +5.5% | $10.8B +3.9% | $10.4B +4.7% | $10.0B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 4.2% -0.4pp | 4.6% -0.9pp | 5.6% -0.2pp | 5.8% +0.1pp | 5.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | $9.1B -3.1% | $9.4B +10.3% | $8.5B +1.0% | $8.4B +6.4% | $7.9B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 3.3% -0.5pp | 3.8% -0.6pp | 4.4% -0.3pp | 4.7% +0.1pp | 4.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.4B -3.8% | $1.4B -0.8% | $1.4B +17.8% | $1.2B +1.7% | $1.2B | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.5B +63.0% | -$4.1B -37.2% | -$3.0B -5603.8% | -$53.0M +95.4% | -$1.2B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $7.6B +44.1% | $5.3B -4.4% | $5.5B -34.3% | $8.4B +23.7% | $6.8B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 2.8% +0.6pp | 2.1% -0.7pp | 2.8% -1.8pp | 4.7% +0.8pp | 3.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.3B -9.8% | $1.5B +957.4% | $141.0M -91.3% | $1.6B +17.9% | $1.4B | $1.3B | -$1.6B | $745.2M |
| Net Income | $6.0B +73.5% | $3.4B -33.5% | $5.2B -23.0% | $6.7B +24.8% | $5.4B | $4.9B | $4.8B | $4.7B |
| Net Margin | 2.2% +0.8pp | 1.4% -1.3pp | 2.6% -1.1pp | 3.7% +0.6pp | 3.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $22 +82.0% | $12 -30.3% | $18 -18.9% | $22 +36.3% | $16 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $22 +82.9% | $12 -30.3% | $17 -18.8% | $21 +35.9% | $16 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $265.9M -5.1% | $280.3M -5.6% | $296.9M -5.2% | $313.1M -7.4% | $338.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $265.9M -6.1% | $283.2M -4.6% | $296.9M -5.2% | $313.1M -8.2% | $341.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
CVS Health Corporation
NYSE:CVS
$129.94B
Elevance Health Inc.
NYSE:ELV
$87.39B
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$63.35B
Cencora, Inc.
NYSE:COR
$54.86B
Becton, Dickinson and Company
NYSE:BDX
$52.82B
Cardinal Health, Inc.
NYSE:CAH
$52.49B
Humana Inc.
NYSE:HUM
$45.41B
IDEXX Laboratories, Inc.
NASDAQ:IDXX
$44.09B
Zoetis Inc.
NYSE:ZTS
$33.61B
Centene Corporation
NYSE:CNC
$32.41B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CI generate?
Cigna Corporation (CI) reported $274.95B of revenue in fiscal 2025.
Is CI profitable?
Cigna Corporation (CI) reported $5.96B of net income, with a net margin of 2.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.